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Allergic reactions are associated with several 
hypersensitivity diseases including asthma, rhi-
noconjunctivitis, contact dermatitis, urticaria, 
anaphylaxis, and insect, drug, and food allergy. 
These diseases can affect all age groups and 
have reached epidemic proportions worldwide 
with increasing incidence over the last decades 
(Holgate, 1999). The most common forms of 
allergies, such as pollen, house dust, or animal 
dander allergies, are dependent on type 2 T cell 
responses (Georas et al., 2005), leading to the 
generation  of  IL-4  and  IgE.  IgE  antibodies 
have a short half-life in serum but are stable if 
bound to Fc receptors on circulating basophils 
and, in particular, tissue mast cells (Vieira and 
Rajewsky, 1988). Cross-linking of the IgE–FcI 
receptor complex on these cells by allergen 
leads to degranulation within seconds, liberat-
ing a variety of preformed inflammatory medi-
ators. The clinical effects attended by such 
allergic reactions vary according to the site of 
basophil and mast cell activation. Although   
inhalation or ingestion of allergens activates 
mucosal mast cells, i.v. or s.c. antigen entry acti-
vates circulating basophils and connective tissue 
mast cells.
Most current therapies for the treatment of 
allergies block mast cell effector molecules (e.g., 
histamines) or nonspecifically suppress immune 
responses (e.g., steroids). Although effective, 
these treatments fail to affect the immunological 
conditions causing the allergies. In addition, dif-
ferent vaccination or desensitization strategies 
have been investigated, including the usage of 
allergen-derived peptides (Francis and Larché, 
2005), recombinant hypoallergenic derivates 
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Allergen-specific desensitization is the only disease-modifying therapy currently available 
for the treatment of allergies. These therapies require application of allergen over several 
years and some may induce life-threatening anaphylactic reactions. An ideal vaccine for 
desensitization should be highly immunogenic and should alleviate allergic symptoms upon 
few injections while being nonreactogenic. We describe such a vaccine for the treatment of 
cat allergy, consisting of the major cat allergen Fel d1 coupled to bacteriophage Q-derived 
virus-like particles (Q–Fel d1). Q–Fel d1 was highly immunogenic, and a single vaccina-
tion was sufficient to induce protection against type I allergic reactions. Allergen-specific 
immunoglobulin G antibodies were shown to be the critical effector molecules and alleviated 
symptoms by two distinct mechanisms. Although allergen-induced systemic basophil degran-
ulation was inhibited in an FcRIIb-dependent manner, inhibition of local mast cell degranu-
lation in tissues occurred independently of FcRIIb. In addition, treatment with Q–Fel d1 
abolished IgE memory responses upon antigen recall. Despite high immunogenicity, the 
vaccine was essentially nonreactogenic and vaccination induced neither local nor systemic 
anaphylactic reactions in sensitized mice. Moreover, Q–Fel d1 did not induce degranulation 
of basophils derived from human volunteers with cat allergies. These data suggest that 
vaccination with Q–Fel d1 may be a safe and effective treatment for cat allergy.
© 2009 Schmitz et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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This vaccine was strongly immunogenic in mice, yielding 
high and long-lasting antigen-specific serum IgG titers after 
only a single immunization. Vaccination with Q–Fel d1 re-
sulted in strongly reduced immediate type I allergic responses 
in a mouse model of mast cell degranulation, vascular leakage, 
and anaphylaxis and completely abolished IgE B cell memory 
responses upon antigen recall. Strikingly, coupling of Fel d1 
to Q-VLPs essentially abrogated its ability to induce allergic 
responses in mice or the degranulation of human basophils 
derived from allergic individuals. Thus, displaying Fel d1 on 
VLPs enhanced its immunogenicity and therapeutic efficacy 
while strongly reducing its reactogenicity.
RESULTS
Generation and structure of recombinant Fel d1 protein  
and vaccine design
To generate a vaccine for the treatment of cat allergies, we 
displayed the major cat allergen Fel d1 in a highly ordered 
fashion on Q VLPs, which have been shown to be a potent 
carrier for various antigens in mice and humans (Bachmann   
et al., 1993; Jegerlehner et al., 2002a,b; Maurer et al., 2005; 
Spohn et al., 2005; Kündig et al., 2006; Ambühl et al., 2007; 
Tissot et al., 2008). To this end, a covalent dimer of Fel d1 
was generated and expressed in Escherichia coli (rFel d1). The 
details of the constructs are schematically shown in Fig. 1 A. 
rFel d1 was coupled to Q VLPs (Q–Fel d1) and analyzed 
by SDS-PAGE. Densitometric analysis of the coupling prod-
ucts indicated 40% coupling efficiency, corresponding to   
70 rFel d1 molecules per Q VLP (Fig. 1 B). Thus, there is 
roughly 20 µg rFel d1 per 50 µg of vaccine. Identities of the 
different bands were confirmed by Western blotting using 
anti-His tag and anti-Q antibodies (unpublished data).
To determine the immunogenicity of the vaccine, BALB/c 
mice were immunized on days 0 and 14 by s.c. injections with 
Q–Fel d1 or, as a control, with equivalent amounts of free 
rFel d1 mixed with Q. Fel d1–specific IgG titers were deter-
mined at the indicated time points by ELISA. A single vaccina-
tion of mice with Q–Fel d1 induced a Fel d1–specific IgG 
response (Fig. 1 C), which consisted of similar amounts of anti-
gen-specific IgG1 and IgG2a isotypes (Fig. S1). This response 
could be boosted by the second injection of the vaccine on   
day 14 (Fig. 1 C). rFel d1 mixed with Q also induced similar 
amounts of allergen-specific IgG1 and IgG2a isotypes (Fig. S1); 
however, titers were much lower overall than those achieved 
with the coupled product. (Fig. 1 C). These data demonstrate 
that coupling of Fel d1 to Q strongly enhances its immuno-
genicity. Of note, antigen-specific IgE titer could not be de-
tected upon Q–Fel d1 immunization (Fig. S1), indicating that 
the construct is nonallergenic.
Coupling of Fel d1 to Q strongly reduces  
its reactogenicity in vivo
Considering that anaphylactic reactions are the major draw-
back of current desensitization therapies, we set out to inves-
tigate the ability of Q–Fel d1 to trigger mast cell–mediated 
type I hypersensitivity reactions. To this end, BALB/c mice 
(Niederberger et al., 2004; Saarne et al., 2005), oligonucle-
otides with CpG motives (Hessel et al., 2005), or allergen 
conjugated to carbohydrate-based particles (Andersson et al., 
2004). However, only a few disease-modifying therapies for 
allergy have been approved so far. These immunotherapies 
consist of either multiple s.c. injections of increasing doses of 
allergen or multiple sublingual or oral administration of the   
allergen,  resulting  in  long-term  desensitization  (Till  et  al., 
2004). Although these allergen-specific immunotherapies 
have shown successes (Durham and Till, 1998), the proce-
dures are time consuming and require 1–3 yr of regular treat-
ments (Hedlin et al., 1986, 1991). Moreover, this therapy 
bears a high risk for anaphylactic reactions, especially after ad-
ministration of higher allergen doses (Cox and Coulter, 1997; 
Bousquet et al., 1998).
The mechanism by which this specific immunotherapy 
affects allergies is poorly understood. The reduction in aller-
gic symptoms by this treatment has been hypothesized to be 
at least partly mediated by a shift from Th2 toward a Th1 re-
sponse or the induction of regulatory T (T reg) cells (Akdis   
et al., 2005). Alternatively, and not mutually exclusive, the 
balance  between  allergen-specific  IgE  and  IgG  antibodies 
may regulate mast cell and basophil activity. In fact, Hulett   
et al. (1993) identified an FcR, with a binding site for IgG, 
which regulates high affinity IgE receptor–mediated mast cell 
activation (Daëron et al., 1995b). It is well established that 
the FcRIIb (FcIIb receptor), expressed on mouse and hu-
man basophils and mast cells (Bischoff, 2007), can down-reg-
ulate FcRI signaling by cross-linking of the FcRI–IgE and 
FcRIIb–IgG-Ag complex (Daëron et al., 1995a; Katz, 2002; 
Bruhns et al., 2005; Kraft and Kinet, 2007; Nimmerjahn and 
Ravetch, 2008). Indeed, a fusion molecule between the cat 
allergen Fel d1 and the constant part of IgG1 has recently 
been shown to inhibit allergic symptoms by cross-linking of 
FcRIIb with FcRI in a mouse model of asthma (Zhu et al., 
2005; Terada et al., 2006). In addition to signaling through 
FcRIIb, allergen-specific IgG antibodies may sequester   
allergens  and  hence  prevent  their  binding  to  IgE–FcRI 
complexes. Moreover, it has been shown that the ratio of   
allergen-specific IgE and IgG antibodies may affect presenta-
tion of allergen-derived epitopes to T cells (Wachholz and 
Durham, 2004). Thus, allergen-specific antibodies may have 
multiple ways to modulate allergic responses.
We have previously shown that antigens displayed in a 
repetitive fashion on virus-like particles (VLPs) derived from 
the coat protein of the bacteriophage Q are highly immuno-
genic in mice (Jegerlehner et al., 2002a,b; Lechner et al., 
2002; Spohn et al., 2005) and humans (Maurer et al., 2005; 
Kündig et al., 2006; Ambühl et al., 2007; Tissot et al., 2008). 
Because bacterial host RNA is incorporated into the VLPs 
during self-assembly inside bacteria, Q-VLPs provide Toll-
like receptor ligands, which induce strong IgG2a/c-domi-
nated  antibody  responses  (Forsbach  et  al.,  2007,  2008; 
Jegerlehner et al., 2007). In the present study, the major   
cat allergen Fel d1 was coupled in an oriented fashion to   
Q-VLPs, resulting in a highly repetitive form of the allergen. JEM VOL. 206, August 31, 2009 
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vascular leakage was strongly reduced if the pricks were per-
formed with equivalent amounts of rFel d1 coupled to Q. 
Densitometric quantification of dye extravasation revealed 
that Q–Fel d1 induced three to five times less vascular leak-
age than equivalent amounts of rFel d1 (Fig. 2 A, right).
To assess systemic anaphylactic reactions, sensitized mice 
were challenged i.v. with Q–Fel d1 or rFel d1. Injection of 
rFel d1 induced anaphylactic syndromes in a dose-dependent 
manner as documented by a rapid drop in temperature   
(Fig. 2 B). It is important to note that animals challenged 
with the highest dose of allergen had to be euthanized after 
30 min because of the strong anaphylactic reaction induced. 
In marked contrast, injection of Q–Fel d1 did not induce 
systemic anaphylaxis at any concentration tested. Likewise, 
vascular leakage in ears upon systemic mast cell degranula-
tion was only observed in animals that had been challenged   
with rFel d1 (Fig. 2C). Because endotoxin contaminations   
in either Q–Fel d1 or rFel d1 preparations could interfere   
with the anaphylactic response, the endotoxin content of the 
Q–Fel d1 and r Fel d1 batches used in our experiments were 
determined. Q–Fel d1 and rFel d1 exhibited similar low 
levels of endotoxin (Fig. S2), excluding an influence of endo-
toxin on the allergic response observed.
Having demonstrated that covalent coupling of rFel d1 to 
Q VLPs strongly reduces its potential to trigger allergic re-
sponses in mice, we set out to confirm this with human cells. 
Therefore, heparinized whole blood of cat allergic and non-
allergic donors was collected and incubated with increasing con-
centrations of either rFel d1 or Q–Fel d1. rFel d1 induced 
strong degranulation of basophils in cat-allergic individuals. In 
accordance with the observations in the previous paragraph, 
Q–Fel d1 hardly induced human basophil degranulation in 
three out of three allergic individuals tested (Fig. 2 D and not 
depicted). Neither rFel d1 nor Q–Fel d1 induced basophil 
degranulation in nonallergic individuals (unpublished data). 
Collectively, these results demonstrate that coupling of Fel d1 
to Q VLPs dramatically reduces its reactogenicity in mice in 
vivo and human basophils in vitro.
Vaccination with Q–Fel d1 protects from systemic 
anaphylaxis and inhibits local mast cell degranulation  
in vivo in an allergen-specific manner
Next, we addressed whether Q–Fel d1 was able to desensi-
tize allergic mice. To this end Fel d1–sensitized BALB/c mice 
were vaccinated once with Q–Fel d1 or, as a control, in-
jected with Q, PBS, or Fel d1 alone (Fig. 3 A). s.c. adminis-
tration of PBS, Q, or Q–Fel d1 did not induce anaphylactic 
reactions in allergic mice, as documented by constant body 
temperature after injection (not depicted). In marked con-
trast, s.c. vaccination with free Fel d1 induced such strong 
anaphylactic reactions that mice had to be euthanized 30–40 
min after injection and could not be used for further experi-
ments (unpublished data). Because of sensitization, all experi-
mental groups had mounted a Fel d1–specific IgG response 
by day 34 and vaccination with Q–Fel d1 led to a 10-fold 
increase in Fel d1–specific IgG titers at day 45 (Fig. 3 B).   
were sensitized with Fel d1 and, 3 wk later, the right ears 
were pricked with Q–Fel d1 and the left ears with rFel d1. 
As  expected,  ear  pricks  performed  with  rFel  d1  induced 
strong mast cell degranulation, as visualized by dye extrava-
sation in a dose dependent manner (Fig. 2 A, left). In contrast, 
Figure 1.  Production and coupling of recombinant Fel d1 protein. 
Fel d1 was cloned, expressed, purified, and coupled to VLPs as described in 
Materials and methods. (A) Schematic representation of rFel d1. Chain  
1 and 2, His tag with (G4S)x3 linker, and the Cystein used for coupling are 
shown. (B) Analysis of coupling reactions. Fel d1 was coupled to Q-VLPs 
and analyzed by SDS PAGE (12%). 1, prestained protein marker (broad 
range 5–123); 2, untreated Q; 3, SMPH-derivatized Q; 4, Fel d1-15aa-
HC; 5, purified Q–Fel d1-15aa-HC. Coupling products are marked with 
asterisks. All lanes (1–5) originate from one gel. Lanes presenting products 
of unimportant purification steps were cropped out between Fel d1-15aa-
HC and the purified end product Q–Fel d1-15aa-HC. (C) Naive BALB/c 
mice were immunized s.c. with either 50 µg Q–Fel d1 or 20 µg Fel d1 
mixed with 30 µg Q on days 0 and 14. Mice were bled on day 14, 21, and 
28 and anti–Fel d1 IgG serum antibody titers determined by ELISA. Sub-
class titers are provided in Fig. S1. Mean Fel d1–specific IgG titers ± SD  
(n = 3) are shown. Data are representative of three independent experi-
ments with three mice per group. **, P < 0.005; ***, P < 0.0005.1944 VACCINATION WITH Q–FEL D1 PROTECTS MICE AGAINST CAT ALLERGY | Schmitz et al.
Figure 2.  Reduced in vitro and in vivo reactogenicity of Fel d1 coupled to Q. BALB/c mice were sensitized as described in Materials and meth-
ods and challenged on day 21 with rFel d1 or Q–Fel d1. (A) Intradermal ear prick test with different amounts of free rFel d1 into the right ears or cou-
pled rFel d1 (Q–Fel d1) into the left ears. One representative ear pair out of three is shown (left). Mean net intensity of pricked ears ± SD (n = 3) from 
the densitometric quantification of dye extravasation is also shown (right). Data are representative of two independent experiments with three mice per 
group for both experiments. (B) Mice were injected with 2, 1, or 0.5 µg of free or coupled rFel d1 i.v. Mean temperature changes (°C) in Fel d1– (filled sym-
bols) or Q–Fel d1-injected mice (open symbols) ± SD are shown (n = 3). (C) 70 min after i.v. injection of either free or coupled Fel d1, active systemic 
anaphylaxis documented by diffuse dye leakage in the skin was examined. One representative mouse out of three is shown. Data are representative of 
two independent experiments with three mice per group. (D) Heparinized human whole blood of two cat allergic donors was incubated with rFel d1 or 
Q–Fel d1. Basophil degranulation (in percentage) was determined by CD63 surface expression on CD123+/HLA-DR cells by flow cytometry (Sanz et al., 
2002). Data are representative of three independent experiments with these volunteers. *, P < 0.05.JEM VOL. 206, August 31, 2009 
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To investigate the effect of vaccination on local allergic 
reactions, ear skin prick tests with rFel d1 were performed in 
a different set of mice as outlined in Fig. 3 A. Allergen chal-
lenge induced mast cell degranulation and subsequent vascular 
leakage in Q and PBS control groups (Fig. 3 D). In contrast, 
Q–Fel d1-treated animals were protected from mast cell de-
granulation. In fact, dye extravasation was almost reduced to 
the levels observed in nonsensitized naive mice (Fig. 3 D). 
These experiments show that treatment with Q–Fel d1 is 
The predominant subclass was IgG1, presumably because Fel 
d1–specific memory B cells expressing IgG1 were preferentially 
boosted (Fig. S3). To assess whether vaccinated animals were 
protected from allergic reactions, all groups were challenged 
i.v. with Fel d1 and body temperature was monitored at reg-
ular intervals. A severe drop in body temperature was ob-
served in mice that had been treated with PBS or Q (Fig. 3 C). 
In contrast, Q–Fel d1-treated animals were completely pro-
tected from anaphylactic reactions.
Figure 3.  Inhibition of mast cell degranulation and protection from active systemic anaphylaxis in Q–Fel d1-vaccinated mice. (A) Sche-
matic outline of the experiment. (B) Serum of individual mice was collected before (d35) and after (d45) vaccination. Mean Fel d1–specific IgG titers ± SD 
are shown (n = 7). (C) 11 d after vaccination, all groups were challenged i.v. with rFel d1 and body temperature was measured at regular intervals. 
Changes in body temperature in degrees celsius ± SD (n = 3) are shown on the left and mean area above the curves ± SD (n = 3) on the right. Individual 
areas above the curves were determined and compared by one-way analysis of variance (ANOVA) using Bonferroni’s post test (PBS/Q, NS; PBS/Q–Fel d1,  
P < 0.01; Q/Q–Fel d1, P < 0.01. (D) Ear prick tests with rFel d1 in naive, PBS-, Q-, or Q–Fel d1-treated mice. One representative mouse of each group 
is shown on the left. Mean net intensity of pricked ears ± SD (n = 4) from the densitometric quantification of dye extravasation is shown on the right.  
(E) OVA/rFel d1–sensitized mice were vaccinated with Q or Q–Fel d1 and pricked with OVA in the left ear and rFel d1 in the right ear. Mean net 
  intensities ± SD (n = 5) are shown. Q versus Q–Fel d1/OVA challenge was NS. Net intensity of the Q–Fel d1/Fel d1-challenged group is significantly 
reduced as compared with all other groups. All data shown are representative of four independent experiments with at least the same number of mice 
per group as shown in A–D. *, P < 0.01; **, P < 0.005; ***, P < 0.0005.1946 VACCINATION WITH Q–FEL D1 PROTECTS MICE AGAINST CAT ALLERGY | Schmitz et al.
Q–Fel d1 vaccination prevents the immediate type I 
allergic response upon i.p. antigen challenge
To further characterize an influence of vaccination on the 
immediate type I allergic response, sensitized and vaccinated 
mice were challenged i.p. with rFel d1 (Fig. 4 A). In the Q-
immunized control group, strong i.p. vascular leakage was 
observed as documented by increased levels of albumin and 
number of infiltrating cells in the peritoneum and increased 
histamine levels in serum (Fig. 4, B–D). In fact, i.p. rFel d1 
administration resulted in strong anaphylactic reactions 40 min 
after challenge in Q-vaccinated control mice, as docu-
mented by a lethargic state, shaggy hair, strong hunched back, 
closed eyes, and red skin (Fig. 4 E). In contrast, mice treated 
with Q–Fel d1 displayed significantly lower i.p. albumin 
levels and cell counts as well as reduced serum histamine   
safe, prevents local and systemic allergic reactions in vivo, and, 
thus, efficiently desensitizes mice against Fel d1.
To address whether Q–Fel d1 vaccination inhibits mast 
cell degranulation in an antigen-specific manner, mice were 
sensitized against OVA and rFel d1. Sensitized mice were vac-
cinated subsequently with either Q or Q–Fel d1, 2 wk be-
fore ear prick tests with either OVA (left ear) or rFel d1 (right 
ear) were performed. Strong mast cell–mediated vascular leak-
age was observed in the control group, which was pricked   
either with rFel d1 or OVA, indicating that the animals had 
been equally sensitized to both allergens (Fig. 3 E). As ob-
served in the previous paragraph, mice treated with Q–Fel 
d1 hardly reacted to rFel d1 challenge. However, Q–Fel d1 
treatment did not influence vascular leakage induced by OVA, 
demonstrating allergen specificity (Fig. 3 E).
Figure 4.  Q–Fel d1 vaccination blocks type I allergic reactions after i.p. allergen challenge. (A) Schematic outline of the experiment. BALB/c 
mice were sensitized and, 4 wk later, vaccinated s.c. with Q or Q–Fel d1. 12 d later, mice were challenged i.p. with rFel d1. (B–D) Peritoneal vascular 
leakage was determined by measurement of peritoneal albumin concentrations (B), peritoneal cell influx (C), and serum histamine levels (D) upon antigen 
challenge. Mean values ± SD are shown (n = 5). (E) Pictures of representative animals of each experimental group, 40 min after i.p. rFel d1 challenge.  
Q control animals displayed typical signs of an anaphylactic reaction including reduced activity, shaggy hair, closed eyes, and swollen and red feet and 
ears. (F) Fel d1–specific IgG (left) and Fel d1–specific IgE (right) titers. Subclass titers are provided in Fig. S4. Mean half-maximal antibody titers ± SD (n = 5) 
are shown. (G) ELISPOT assays were performed 1 wk after Fel d1 challenge as described in Materials and methods. Numbers of IL-4 producing cells per  
2 × 105 spleen cells ± SD (n = 4) are shown (Q–Fel d1–PBS vs. Q–Fel d1–Fel d1 challenge, NS). In addition, similar results were obtained with purified  
CD4+ T cells (not depicted). The data shown are representative of two independent experiments with the same number of mice per group. *, P < 0.05; **,  
P < 0.005; ***, P < 0.0005.JEM VOL. 206, August 31, 2009 
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and CD4+ T cells are not required for Q–Fel d1-mediated 
desensitization against local allergen challenge. Likewise, 
Q–Fel d1 treatment prevented systemic anaphylactic reac-
tions independent of CD4+ T cells (Fig. 5 D). In addition, 
experiments with IL-10/ mice showed no dependence of 
Q–Fel d1-mediated local (Fig. 6 A) and systemic (Fig. 6 B) 
desensitization on the regulatory cytokine IL-10.
To investigate the role of Fel d1–specific antibodies in the 
desensitization process, serum from sensitized mice that had 
been vaccinated with Q or Q–Fel d1 was transferred into 
recipient mice, 4 wk after their sensitization. The Fel d1–spe-
cific IgG titers in all experimental groups were similar before 
the transfer and increased in the experimental groups that had 
received serum from Q–Fel d1-vaccinated mice (Fig. 6 C, 
left). As shown in Fig. 6 C (right), transfer of serum from sen-
sitized and Q–Fel d1-vaccinated mice strongly reduced vas-
cular leakage in allergic recipient mice challenged with allergen, 
3 d after serum transfer. Similar results were obtained with pu-
rified total IgG (unpublished data). Thus, Fel d1–specific IgGs 
are key effector molecules in the desensitization process and 
are able to block IgE-mediated mast cell degranulation.
The inhibitory FcRIIb-receptor is essential for Q–Fel  
d1-mediated protection from systemic anaphylaxis
To investigate the mechanism of protection by Fel d1–spe-
cific IgG, we investigated whether an inhibitory signaling event 
through FcRIIb was required. Hence, WT and FcRIIb/ 
mice were sensitized and vaccinated 4 wk later with Q or 
Q–Fel d1 (Fig. 7 A). In line with previous studies (Takai   
et al., 1996), FcRIIb/ mice exhibited slightly higher anti-
gen-specific antibody titers upon sensitization compared with 
WT mice (unpublished data). Nevertheless, vaccination with 
Q–Fel d1 strongly increased Fel d1–specific IgGs in WT 
and FcRIIb/ mice reaching similar levels (Fig. 7 B). i.v. 
antigen challenge 2 wk after control Q treatment led to a 
strong anaphylactic reaction in both WT and FcRIIb/ 
mice. As reported previously (Takai et al., 1996; Ujike et al., 
1999), FcRIIb/ mice displayed a stronger anaphylactic 
response than WT control mice (Fig. 7 C). Strikingly, although 
Q–Fel d1-vaccinated WT mice were completely protected 
from acute systemic anaphylaxis, Q–Fel d1-vaccinated 
FcRIIb/ mice were not protected at all (Fig. 7 C). To 
exclude  that  the  increased  sensitivity  for  anaphylaxis  in 
FcRIIb/ mice was responsible for the absence of protec-
tion upon Q–Fel d1 vaccination, we repeated this anaphy-
laxis experiment using a lower challenge dose of Fel d1 for 
FcRIIb/ than for WT mice. As shown in Fig. S6, control 
Q-vaccinated WT and FcRIIb/ mice experienced an 
almost identical anaphylactic response under these experi-
mental conditions. Although Q–Fel d1-vaccinated WT 
mice were protected from anaphylaxis, Q–Fel d1-vacci-
nated FcRIIB/ mice experienced a strong anaphylactic 
response, which was not significantly different from the re-
sponse of control mice, demonstrating that FcRIIb signal-
ing was indeed essential for Q–Fel d1-mediated prevention 
of anaphylaxis.
levels than control mice (Fig.4, B–D). Moreover, these mice 
showed no physical signs of anaphylaxis (Fig. 4 E).
We next monitored Fel d1–specific IgG and IgE titers   
in these mice at the indicated time points (Fig. 4 A). After 
sensitization, similar Fel d1–specific IgG titers were mea-
sured in all animals. Vaccination with Q–Fel d1 boosted 
the anti–Fel d1 IgG response and allergen challenge further 
increased anti–Fel d1 IgG titers in serum (Fig. 4 F, left). 
The subclass produced upon Q–Fel d1 vaccination was 
predominated by boosted preexisting IgG1 isotypes but also 
antigen-specific IgG2a and IgG2b antibodies were induced 
upon Q–Fel d1 vaccination (Fig. S3). As expected, upon 
Q vaccination no Fel d1–specific IgGs were induced or 
boosted (Fig. 4 F, left) and antigen-specific IgG1 and IgG2b 
isotypes were only induced upon allergen challenge on day 40 
(Fig. S3). Interestingly, although Q-injected control ani-
mals showed a strong boosting of the preexisting IgE re-
sponse upon allergen challenge, in Q–Fel d1-treated ani-
mals no boosting of the IgE response was observed upon 
challenge with allergen (Fig. 4 F, right). This result indi-
cates that vaccination with Q–Fel d1 not only boosts anti-
gen-specific IgG responses but also prevents IgE B cell 
memory responses upon allergen recall. In an attempt to 
elucidate how Q–Fel d1 vaccination prevents boosting of 
IgE responses upon antigen challenge, we examined whether 
the Fel d1–specific T helper cell response was affected upon 
Q–Fel d1 vaccination. To this end, we vaccinated sensi-
tized mice with Q or Q–Fel d1 and challenged mice   
2 wk later either with Fel d1 or PBS. 7 d later, IL-4 ELISPOT 
assays were performed with spleen cells from the different 
groups of mice. Sensitized and nonvaccinated mice chal-
lenged with PBS or Fel d1 were used as controls. Confirm-
ing previous experiments, Q–Fel d1 vaccination boosted 
antigen-specific IgG titers and prevented IgE memory re-
sponses  upon  later  antigen  challenge  (unpublished  data). 
Furthermore, Fel d1 challenge induced an increase in IL-4–
producing Fel d1–specific T helper cell numbers in sensi-
tized control and Q-vaccinated animals (Fig. 4 G). In 
contrast, Fel d1 challenge in sensitized Q–Fel d1-vacci-
nated mice did not lead to a significant increase of IL-4–
producing T helper cells numbers, indicating that vaccination 
with Q–Fel d1 prevents expansion of these cells and, per-
haps, thereby also IgE isotype switching.
Q–Fel d1 desensitization is mediated by Fel d1-specific 
serum IgG
In light of the recent studies implicating T cells (Lu et al., 
2006; Kashyap et al., 2008) and IL-10 (Grimbaldeston et al., 
2007; Kennedy Norton et al., 2008) in mast cell function, we 
set out to test whether these components of the immune sys-
tem were involved in Q–Fel d1-mediated desensitization. 
Therefore, we first depleted either T reg cells or CD4+ T 
cells in sensitized and vaccinated mice by the injection   
of anti-CD25 (pc61) or anti-CD4 antibodies, respectively. 
Depletion of these cell populations was confirmed by FACS 
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Figure 5.  T reg cells and CD4+ effector T cells are dispensable for Q–Fel d1 desensitization. (A) Schematic outline of the experiment. After 
sensitization and vaccination, T reg cells or CD4+ T cells were depleted by administration of anti-CD25 or anti-CD4, respectively. Control mice received 
either GL113 isotype Abs or PBS. (B and C) Mean net intensity of dye extravasation after skin pricking in T reg cell–depleted ± SD (n = 4; B) and CD4+-
depleted mice ± SD (n = 5; C). (D) Anaphylaxis in sensitized mice treated with Q or Q–Fel d1, 2 d after CD4+ T cell depletion. Mean changes in body 
temperature ± SD (n = 4) are shown on the left and mean areas above the curves ± SD (n = 4) are shown on the right. Individual areas above the curves 
were determined and compared by one-way ANOVA using Bonferroni’s post test (PBS: Q/Q–Fel d1, P < 0.001; anti-CD4: Q/Q–Fel d1, P < 0.001;  
Q–Fel d1: PBS vs. anti-CD4, NS). Data shown are representative of three independent experiments with four mice per group. B and C: *, P < 0.05; **,  
P < 0.005; ***, P < 0.0005. D: **, P< 0.001.
To address whether local mast cell degranulation in the skin 
was also affected by FcRIIB expression, we challenged sensi-
tized and vaccinated FcRIIb/ mice intradermally with Fel d1. 
In contrast to the systemic reaction to allergen, FcRIIb/ 
mice treated with Q–Fel d1 were equally well protected from 
intradermal allergen challenge as WT mice (Fig. 7 D).
Collectively, these results strongly suggest that acute sys-
temic anaphylactic reactions can be prevented by inhibitory 
signaling mediated by IgG-Fel d1 immune complexes bound 
to FcIIb receptor on circulating basophils. Interestingly, in-
hibitory signaling through FcIIb receptor is not needed to 
prevent local mast cell degranulation upon intradermal aller-
gen challenge. Under those circumstances, the slowly diffus-
ing allergen might be sequestered within the tissue by the 
induced IgGs at the injection site and hence prevented from 
reaching IgEs bound to FcRI on mast cells.JEM VOL. 206, August 31, 2009 
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Figure 6.  Q–Fel d1-mediated desensitization is mediated by antigen-specific IgG. Mice were sensitized and vaccinated as described in  
Fig. 5 A. (A) Mean net intensity of dye extravasation after skin pricking of Q or Q–Fel d1-treated WT and IL-10/ mice ± SD (n = 3). (B) Anaphylaxis in 
sensitized WT (+/+) and IL-10/ mice (/) treated with Q or Q–Fel d1. Mean changes in body temperature ± SD (n = 4) are shown on the left and 
mean areas above the curves ± SD (n = 4) are shown on the right. Individual areas above the curves were determined and compared by one-way ANOVA 
using Bonferroni’s post test (WT: Q/Q–Fel d1, P < 0.001; IL-10/: Q/Q–Fel d1, P < 0.0001; Q–Fel d1: WT vs. IL-10/, NS). (C) Serum from sensi-
tized and Q- or Q–Fel d1-vaccinated mice was transferred into sensitized mice. Mean half-maximal antibody titers before (day 34) and after (day 37) 
transfer ± SD (n = 3) are shown on the left. Mean net intensity of pricked skin areas ± SD (n = 3) are shown on the right. Data shown are representative 
of two independent experiments with the same number of mice per group. A and C: **, P < 0.005; ***, P < 0.0005. B: **, P < 0.001; ***, P < 0.0001.1950 VACCINATION WITH Q–FEL D1 PROTECTS MICE AGAINST CAT ALLERGY | Schmitz et al.
might be down-regulated upon Q–Fel d1 vaccination. First, 
it is possible that binding of IgG–Fel d1 complexes to the 
FcIIb receptor, which is also expressed on B cells, would 
mediate  inhibition  of  B  cell  function  (Muta  et  al.,  1994; 
Daëron et al., 1995a). In this case, inhibition would specifi-
cally affect IgE and not IgG B cell responses because antigen-
specific IgG is strongly boosted upon vaccination. However, 
using sensitized FcRIIb/ mice for Q–Fel d1 vaccination, 
we found that despite the absence of the inhibitory FcIIb re-
ceptor on B cells, vaccination with Q–Fel d1 still blocked 
IgE B cell memory responses (unpublished data). We there-
fore believe that an inhibitory FcRIIb signaling on B cells is 
not the cause for the abrogated IgE B cell response upon anti-
gen recall. A second possibility for how Q–Fel d1 vaccina-
tion could affect long-term IgE responses may be via a direct 
or indirect inhibitory effect of Q–Fel d1 on T helper cell   
responses, lowering IL-4 production and, consequently, IgE 
isotype switching. Indeed, ELISPOT assays performed with 
splenocytes from sensitized, vaccinated, and antigen-chal-
lenged mice showed that Q–Fel d1-vaccinated mice did not 
develop an increased IL-4 response upon allergen challenge, 
which is different from control mice. Thus, Q–Fel d1 seems 
to be able to block expansion of Th2 cells upon allergen chal-
lenge. We also performed IFN- ELISPOT assays but have not 
observed an increased Th1 response in Q–Fel d1-vaccinated 
mice (unpublished data). This suggests that the reduced Th2 
response is not caused by a shift to Th1 cells. The mechanism 
DISCUSSION
In the present study, we describe a therapy for cat allergy 
based on immunization with the recombinant cat allergen   
Fel d1 displayed on VLPs derived from the bacteriophage Q 
(Q–Fel d1). The therapy is characterized by three key fea-
tures: (a) Q–Fel d1 is highly immunogenic and a single vac-
cination is sufficient for therapy; (b) Q–Fel d1 is essentially 
nonreactogenic; and (c) the effector mechanism of the ther-
apy is based upon the induction of allergen-specific IgGs.
Q-VLPs consist of 180 subunits of a 14-kD coat protein. 
These VLPs elicit strong B cell responses as a result of their 
highly organized and repetitive structures (Jegerlehner et al., 
2002a,b). This feature can be exploited to enhance the immuno-
genicity of self- and foreign antigens. Chemical coupling of 
antigens via a cysteine to surface lysine residues on the VLP 
renders these antigens equally repetitive and consequently im-
munogenic. Moreover, host cell RNA, a ligand for TLR3 and 
TLR7 (Kanzler et al., 2007), is incorporated into the VLPs 
during self assembly of the coat proteins in E. coli serving as a 
build-in adjuvant. Together, these features explain the strong 
IgG responses induced by a single injection of Q–Fel d1.
Interestingly, vaccination of sensitized mice with Q–Fel d1 
resulted in a shutdown of memory IgE responses. Specifically, 
although a strong boosting of the IgE response was observed 
in sensitized control animals, no increase in sensitized and   
vaccinated mice was observed upon subsequent allergen   
challenge. There are different possibilities for how IgE responses 
Figure 7.  Anti–Fel d1 IgG-mediated inhibition of systemic anaphylaxis is mediated by FcRIIb. (A) Schematic outline of the experiment. WT and 
FcRIIb/ mice were sensitized and vaccinated as described in Materials and methods. (B) Anti-Fel d1 IgG serum antibody titers after vaccination. Mean 
half-maximal antibody titers ± SD are shown (WT, n = 4; FcRIIb/, n = 3). (C) 14 d after vaccination, mice were challenged i.v. with rFel d1 and body 
temperature was monitored at regular intervals. Mean changes in body temperature ± SD are shown (n = 3) on the left and mean areas above the curves ± 
SD (n = 3) are shown on the right. Individual areas above the curves were determined and compared by one-way ANOVA using Bonferroni’s post test  
(WT: Q/Q–Fel d1, P < 0.01; FcRIIb/: Q/Q–Fel d1, NS; Q: WT/FcRIIb/, P < 0.01; Q–Fel d1: WT/FcRIIb/, P < 0.0001). (C) Ear prick tests 2 wk  
after vaccination with Q or Q–Fel d1. Dye extravasation was quantified by densitometry and mean net intensities ± SD (WT, n = 4; FcRIIb/, n = 3) 
are shown (WT: Q/Q–Fel d1, P < 0.05; FcRIIB/: Q/Q–Fel d1, P < 0.005; Q–Fel d1: WT/FcRIIb/, NS). All data shown are representative of four 
independent experiments with three mice per group. B and D: *, P < 0.05; **, P < 0.005. C: *, P < 0.01; ***, P < 0.0001.JEM VOL. 206, August 31, 2009 
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IgG antibodies could block mast cell degranulation in the 
mouse skin and that depletion of T reg cells with pc61 did not 
affect Q–Fel d1-mediated desensitization. It is known that 
administration of pc61 leads to incomplete T reg cell deple-
tion because CD4+CD25Foxp3+ cells cannot be depleted 
and may remain functionally present in vivo (Zelenay et al., 
2005; Couper et al., 2007). We therefore performed experi-
ments in mice in which all CD4+ T cells were depleted and, 
again, saw no effect on desensitization. Furthermore, IL-10 
was also not required for the Q–Fel d1-induced desensitiza-
tion. Although successful immunotherapy in humans may in-
volve both T and B cells (Till et al., 2004), as well as induction 
of T reg cells producing IL-10 (Francis et al., 2003; Robinson 
et al., 2004), our data demonstrate that these mediators are not 
important in the immediate type of allergic response upon 
Q–Fel d1 treatment in our mouse model.
Antigen-specific IgG1 was shown to induce anaphylaxis 
in several in vitro and in vivo studies (Ovary et al., 1970; 
Oettgen et al., 1994; Oshiba et al., 1996; Dombrowicz et al., 
1997; Miyajima et al., 1997; Ujike et al., 1999). Yet we find 
in this paper that polyclonal antibodies specific for Fel d1 
dominated by the IgG1 isotype not only fail to sensitize mice 
for anaphylaxis but even prevent IgE-mediated anaphylaxis 
upon allergen challenge. This difference may have several ex-
planations. In the studies where IgG1-mediated anaphylaxis 
was observed, the reaction was induced by passive transfer of 
either antigen-specific IgE or IgG. These elegant studies 
clearly demonstrate that either activation of FcRI–IgE or 
FcRIII–IgG1 upon passive transfer and antigen stimulation 
was able to induce anaphylaxis in mice. Interestingly, IgG1-
mediated  active  systemic  anaphylaxis  has  so  far  only  been 
demonstrated in FcRI/ mice, which show increased ana-
phylactic responses caused by up-regulation of FcRIII re-
ceptor expression (Dombrowicz et al., 1997; Miyajima et al., 
1997). Under these nonphysiological conditions, IgG1 anti-
bodies may preferentially bind to the FcRIII, activating mast 
cell degranulation. In contrast to these studies, we used active 
sensitization with Fel d1 in WT mice. Under these condi-
tions, mast cells/basophils express all relevant Fc receptors on 
their surface and IgG–Ag immune complexes will also bind to 
the inhibitory FcRIIb, inhibiting IgE-mediated anaphylaxis. 
In addition, vaccination of sensitized mice results in specific 
IgG1 as well as IgG2a antibodies. The presence of Fel d1–spe-
cific IgG2a antibodies may have masked a potential ability of 
IgG1 antibodies to trigger anaphylactic reactions.
The results with FcRIIB-deficient mice offer an expla-
nation for how allergen-specific IgGs may inhibit allergic   
reactions. Interestingly, we found that IgG antibodies may 
inhibit the allergic reaction dependent on the allergen local-
ization. The inhibitory FcRIIb was essential for IgG-medi-
ated inhibition of anaphylaxis upon systemic administration 
of the allergen. This suggests that because of the quick diffu-
sion upon systemic exposure complete neutralization of the 
allergen may not be efficient by the circulating antibodies 
and some Fel d1 molecules will reach basophils. Neverthe-
less, Fel d1 will be complexed with antigen-specific IgG,   
of this inhibition will need to be further investigated. One 
further plausible explanation for the Q–Fel d1-mediated ef-
fect could be found in the composition of the Q-VLP itself. 
It is possible that only moderate, and not strong, cross-linking 
of surface Ig is able to drive IgE responses. Indeed, viruses 
rather than parasites exhibit highly organized surface structures 
in a manner similar to Fel d1 displayed on VLPs. IgE responses, 
however, protect against parasitic rather than viral infections. 
Furthermore, Q-VLPs contain RNA, a ligand for TLR 3/7, 
which also drives Th1 and IgG2a responses. Thus, the combi-
nation of high cross-linking activity with TLR7 ligands may 
be able to block IgE memory responses long term. Indeed, 
some of our preliminary results indicated that the shutdown of 
the allergen-specific IgE response was the result of the single-
stranded RNA within the VLPs. Finally, available antigen may 
be limited in Q–Fel d1-vaccinated mice as a result of the 
presence of high anti–Fel d1 IgG titers abolishing the IgE re-
sponse. The abrogated IgE response upon vaccination with 
Q–Fel d1 may have important clinical implications because 
exposure to allergen results in increased IgE levels in allergic 
individuals, which may worsen the allergy. Shutting down this 
allergen-induced IgE response may therefore facilitate long-
term curing of the patients. Indeed, seasonal allergen exposure 
usually boosts IgE responses in allergic individuals, maintain-
ing or even worsening the disease.
The observation that repetitive display of Fel d1 on the 
VLPs resulted in reduced ability to trigger mast cell degranula-
tion may seem somewhat unexpected. Allergens, which are 
typically not multivalent, are not able to strongly cross-link 
IgE-FcRI on mast cells. Hence, allergens displayed on VLPs 
are nonphysiological ligands for mast cells and may, therefore, 
not be able to properly activate the degranulation cascade. In 
fact, it is well known that supraoptimal levels of IgE cross-
linking on mast cells lead to reduced rather than enhanced   
degranulation  (Daëron  and  Lesourne,  2006).  Furthermore, 
because of the linkage of the allergen to the relatively large 
VLPs (30 nm), the in vivo distribution will be fundamentally 
different from free Fel d1. It is important to note that the fail-
ure of Q–Fel d1 to trigger mast cell degranulation is not the 
result of a failure of IgE antibodies to recognize the vaccine 
because both polyclonal and a panel of monoclonal Fel d1–
specific IgE antibodies recognized Fel d1 on Q  (unpublished 
data). Hence, the nonreactogenicity of Q–Fel d1 is not caused 
by an absence of recognition by IgE antibodies but by a failure 
to stimulate mast cells in a productive way.
In this context, T reg cells have been recently described as 
a regulator of mast cell activity by altering IgE receptor ex-
pression and signaling (Kashyap et al., 2008). T reg cells may 
also activate mast cells to mediate local immune suppression 
(Lu et al., 2006). In addition, the regulatory cytokine IL-10, 
which is produced by T reg cells, has been shown to silence 
mast cell function in vivo and in vitro (Grimbaldeston et al., 
2007; Kennedy Norton et al., 2008). In contrast to these stud-
ies, we have found that our VLP-based vaccination primarily 
works through the induction of allergen-specific IgGs rather 
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reacted at room temperature for 30 min with a fivefold molar excess of 
the heterobifunctional chemical cross-linker succinimidyl-6-(b-maleimi-
dopropionamide) hexanoate. Nonreacted cross-linker was removed by 
dialysis against 150 mM PBS, pH 7.4. A 1:1 ratio of rFel d1 and SMPH-
derivatized Q-VLP was incubated for 4 h at room temperature while 
shaking. After covalent coupling, noncoupled rFel d1 was removed by gel 
filtration. The vaccine was analyzed by SDS-PAGE, and immunoblotting 
with anti-Q and anti-penta His antibodies indicated free Q-VLP and 
Q–Fel d1 coupling bands. The intensities of Coomassie blue–stained 
Q–Fel d1 coupling bands were used to calculate coupling efficiency   
by densitometry.
Human basophil degranulation assay
100 µl of heparinized human whole blood of cat allergic and nonallergic do-
nors was incubated with 20 µl of basophil stimulation buffer, with or with-
out the indicated rFel d1 or Q–Fel d1 for 20 min at 37°C. 2 mM fMLP was 
used as a positive control for maximal basophil degranulation. The reaction 
was stopped at 4°C, and cells were stained with anti–CD63-FITC, anti–
CD123-PE, and anti–HLA-DR-PerCP antibodies for 20 min. 2 ml FACS 
lysis solution (BD) were added to lyse erythrocytes and to fix blood cells. 
After a 15-min incubation at room temperature, cells were washed twice 
with PBS and analyzed by flow cytometry. Degranulation was detected via 
CD63 surface expression on CD123+ HLA-DR cells (Sanz et al., 2002; 
FastImmune Assay kit; BD).
Determination of antigen-specific IgG and IgE antibodies
For determination of Fel d1–specific IgG, 96-well ELISA plates (MaxiSorp; 
Nunc) were coated either with 5 µg rFel d1 or with 2 µg Q-VLPs in Car-
bonate buffer at 4°C overnight. After blocking with 2% PBS/BSA solution 
for 2 h, plates were washed five times with PBS/0.05% Tween. Serial dilu-
tions of sera were added to the plates and incubated for 2 h at room tempera-
ture. Plates were than washed five times with PBS/0.05% Tween (PBST). 
Thereafter, HRP0-labeled goat anti–mouse IgG (Jackson ImmunoResearch 
Laboratories) antibodies were incubated at room temperature for 2 h, fol-
lowed by addition of the substrate OPD (O-Phenylenediamine dihydro-
chloride; Sigma-Aldrich). Optical densities were measured at 450 nm. For 
determination of IgE antibodies, a special ELISA was established. 96-well 
plates were coated with 2 µg/ml of rat anti–mouse IgE mAb (BD) diluted in 
carbonate buffer at 4°C overnight. After washing with PBST and blocking 
with PBS/5% BSA solution for 2 h at room temperature, sera of individual 
mice was prediluted 1:20 and then serially diluted 1:3 and incubated for 2 h 
at room temperature. Thereafter, each well was incubated with 500 ng/ml 
rFel d1, diluted in 0.1% PBS/BSA for 30 min at room temperature. After 
washing with PBST, plates were incubated with an anti–Fel d1 IgG-biotin 
antibody (Indoors Biotechnologies) for 1 h at room temperature, followed 
by incubation with HRPO-labeled Streptavidin (BD) for a further 30 min at 
RT. After a final wash with PBST, OPD substrate was added and incubated 
for at least 30 min at room temperature before optical densities were mea-
sured at 450 nm. Half-maximal antibody titers are defined as the reciprocal 
of the dilution leading to half of the OD measured at saturation.
Limulus amebocyte lysate (LAL) test
The LAL endochrome-K assay (Endosafe; Charles River Laboratories) was 
performed according to the manufacturer’s protocol. For standard curve 
preparation, lyophilized control endotoxin standard was dissolved and di-
luted 10× in LAL reagent endotoxin-free water starting with 50 EU in the 
first step. All standard dilutions were prepared in pyrogen-free glass tubes. In 
parallel, samples, including rFel d1 and Q–Fel d1 batches, were also diluted 
10× starting with a 1:100 dilution in the first step. After standard and sample 
preparation, each 100 µl of the standard and sample dilutions was transferred 
to a 96-well microplate in duplicates. As further control, a standard-spiked 
sample was used in which 10 µl of standard was added to each 100-µl sample 
dilution. After transfer of standards and samples, the microtiter plate was in-
cubated for 10 min at 37°C. In the meantime, substrate solutions were pre-
pared and 100 µl of substrate was added to each well starting with the lowest 
engaging cell-bound FcRIIb, capable of blunting FcRI-
mediated signals in WT mice. In contrast, local stimulation 
of mast cells in the skin was inhibited by polyclonal IgG anti-
bodies even in the absence of negative FcRIIb signaling. 
This suggests that Fel d1, which slowly diffuses within tis-
sues, is recognized by specific IgG antibodies, covering up all 
available epitopes on the allergen, and may even result in   
local immune complexes, sequestering the allergen. Hence, 
Fel d1–specific IgG antibodies may simply neutralize the al-
lergen in the periphery. Indeed, earlier studies with blood 
from allergic patients have suggested that IgG4 antibodies 
might exhibit blocking activities in tissues as they compete 
with IgE for binding to mast cells (García et al., 1993). It   
has also been shown that serum obtained from subjects after   
antigen-specific immunotherapy could inhibit IgE-facilitated 
presentation of allergen to grass pollen–specific (van Neerven 
et al., 1999; van Neerven et al., 2004) or birch pollen–spe-
cific T cells (Wachholz et al., 2003; Nouri-Aria et al., 2004). 
Thus, anti–Fel d1-specific IgGs could also compete with IgE 
for antigen binding, inhibiting activation of mast cells in tis-
sues in the absence of an inhibitory FcIIb receptor. In sum-
mary, our data demonstrate that allergens displayed on VLPs 
have the potential to rapidly treat established allergies and 
delineate two different mechanisms how IgG antibodies are 
able to block type I allergic reactions.
MATERIALS AND METHODS
Mice
BALB/c  mice  were  purchased  (Harlan)  at  the  age  of  6  wk  and  BALB/c 
FcRIIb/ mice (N12; Taconic) were purchased at the age of 5–7 wk. BALB/c   
IL-10/ mice were provided by M. Kopf (Swiss Federal Institute, Zürich, 
switzerland) and by U. Eriksson (University Hospital, Zürich, Switzerland). All 
animals were kept under specific pathogen-free conditions at the Biosupport AG 
Wagistrasse, Zürich-Schlieren. All animals were used for experimentation ac-
cording to protocols approved by the Swiss Federal Veterinary Office.
Cloning, expression, purification, and coupling of rFel d1
A covalent fusion of rFel d1 was generated as previously described (Grönlund   
et al., 2003) with modifications. In brief, a complementary DNA encoding 
a covalent dimer of chain 2 and chain 1 of Fel d1 spaced by a 15aa-linker 
(GGGGS)x3 was obtained by PCR amplification using sets of overlapping 
DNA-primers. This complementary DNA was cloned in frame into a modi-
fied version of pET-42a(+) (EMD), leading to the addition of the coding se-
quence for LEHHHHHHGGC at the C terminus of the covalent dimer. 
This sequence contains a His tag for purification, followed by a GGC linker 
used for the coupling of the protein to Q (pET-42T × Fel d1-15aa-HC). 
The plasmid pET-42T × Fel d1-15aa-HC was transformed into the E. coli 
strain BL21(DE3). Expression of rFel d1 was induced at 20°C with 1 mM 
IPTG. After 20 h, cells were harvested, resuspended in native lysis buffer   
(50 mM NaH2PO4, 300 mM NaCl, and 10 mM imidazol, pH 8.0) and dis-
rupted by sonification. rFel d1 was Ni2+ affinity purified, and native folding 
was achieved by intramolecular reshuffling of the disulfide bonds with oxi-
dized glutathione (GSSG; Applichem) and reduced glutathione (GSH; Ap-
plichem) at a molar ratio of 1:1. The reaction was performed for 24 h 
immediately after elution of rFel d1 in the elution buffer by adding 2.5 mM 
GSSG and 2.5 mM GSH at room temperature. Refolded rFel d1 was further 
purified to homogeneity by size-exclusion chromatography (Superdex 75 pg; 
GE Healthcare) equilibrated in PBS.
VLP derived from the bacteriophage Q were expressed in E. coli 
strain JM109 harboring the expression plasmid pQ10 and purified as pre-
viously described (Cielens et al., 2000). For coupling, Q-VLPs were first JEM VOL. 206, August 31, 2009 
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at 37°C. For IL-4 ELISPOT assays, spleen cells of individual mice were 
plated directly on IL-4–coated and FCS-blocked ELISPOT plates, followed 
by incubation of 6 d at 37°C. Alternatively to the usage of whole spleno-
cytes, CD4+ T cells isolated by magnetic cell sorting (MACS microbeads; 
Miltenyi Biotec) were also used for IFN- and IL-4 ELISPOT assays. After 
incubation of cells, ELISPOT assays were performed according to standard 
protocol procedures. In brief, cells were flicked off the plates and washed five 
times with PBS/1% Tween 20, followed by incubation with biotinylated anti–
IFN- or anti–IL-4 antibodies for 2 h at room temperature. Afterward, plates 
were washed five times with PBS/1% Tween 20 and incubated with Streptavi-
din-AP for a further 30 min before the substrate (alkaline phosphatase) was 
added. The substrate reaction was stopped after 8 min by rinsing plates with tap 
water. Plates were dried overnight and ELISPOTs were counted in each well.
Depletion of CD4+ and T reg cells and serum transfer
T reg cells were depleted with an anti-CD25 mAb (clone pc61; provided by   
A. Gallimore, Cardiff University, Cardiff, Wales) by two i.p. administrations of 
250 µg of antibody, 3 and 1 d before antigen challenge. Control mice received 
isotype control Abs (clone GL113; A. Gallimore). CD4+ T lymphocytes were 
depleted with an anti-CD4 mAb (clone YTS 191) by two i.p. administration of 
200 µg of antibody, 2 and 1 d before antigen challenge. Control mice received 
PBS.  Depletion  of  the  respective  cell  populations  (CD4+foxp3+CD25+  or 
CD4+ cells) was determined by flow cytometry 1 d after the last injection of the 
antibodies. With these treatments a reduction of the respective cell types be-
tween 95 and 99% was achieved.
For transfer experiments, serum of sensitized and either Q- or Q–Fel 
d1-vaccinated mice was collected on several days after vaccination for 5 wk. 
Collected serum was pooled and anti-Q and Fel d1 antibody titer were deter-
mined by ELISA as described in an earlier Materials and methods section. Before 
transfer, complement activity in serum needs to be inactivated. To this end,   
serum was inactivated at 56°C for 30 min just before i.p. Q or Fel d1 serum 
transfer was performed, 4 wk after their sensitization. The presence of antigen-
specific IgG antibodies in recipient mice was confirmed by ELISA. 3 d after se-
rum transfer, prick tests with rFel d1 were performed as described above.
Statistical analysis
All statistical analysis comparing two different groups were performed with two 
tailed Student’s t tests. The resulting p-values are either indicated in figure legends 
or with asterisks in figures (*, P < 0.05; **, P < 0.005; ***, P < 0.0005). For sta-
tistical analysis of anaphylaxis experiments, individual areas above the curves were 
determined and compared by one-way ANOVA using Bonferroni’s multiple 
comparison post tests (*, P < 0.01; **, P < 0.001; ***, P < 0.0001).
Online supplemental material
Fig. S1 shows Fel d1–specific IgG1 and IgG2a titers in mice immunized with   
Fel d1 mixed or coupled to Q and Fel d1–specific IgE levels in mice im-
munized with Fel d1 coupled to Q. These parameters were measure in the 
samples from mice shown in Fig. 1 C. Fig. S2 shows the quantification of LPS 
in Fel d1 and Q–Fel d1 samples used for the in vivo experiments. Fig. S3   
shows a time course of the IgG subclasses from the experiment shown   
in Fig. 4 F. Figs. S4 and S5 refer to the experiment shown in Fig. 5 and il-
lustrate the efficiency of the depletion of CD25- and CD4-positive cells, re-
spectively, after injection of monoclonal antibodies. Fig. S6 shows a similar 
anaphylaxis experiment as the one shown in Fig. 7 with WT and FcRIIB/ 
mice but under challenge conditions which lead to similar anaphylaxis in both 
mouse strains. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20090199/DC1.
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concentration. The kinetic measurement with 30-s intervals was performed 
at OD405 nm.
Immunization, sensitization, and vaccination
To test the immunogenicity of the vaccine, 6-wk-old naive BALB/c mice were 
immunized s.c. either with rFel d1 coupled to Q-VLP (50 µg Q–Fel d1)   
or with a mixture of rFel d1 and Q-VLP (30 µg Q + 20 µg rFel d1)   
on days 0 and 14. For Fel d1 sensitization, 6-wk-old naive mice were in-
jected i.p. with 1 µg of natural Fel d1 (Indoors Biotechnologies) mixed in 
200 µl Alum (10 mg/ml Al(OH)3; Alhydrogel; Brenntag Biosector). Alter-
natively, mice were sensitized with a mixture of 1 µg Fel d1 and 1 µg OVA 
(Grade V; Sigma-Aldrich) diluted in 200 µl Alum. For efficacy experiments, 
sensitized mice were vaccinated once s.c. either with PBS, 50 µg Q, or 
Q–Fel d1 in 200 µl PBS, 4–5 wk after sensitization.
rFel d1 antigen challenge in vivo
Ear prick tests. Mice were injected i.v. with 200 µl of Evans blue solution 
(0.5%; Sigma-Aldrich) and anesthetized 30 min later with isoflurane. After-
ward a drop of rFel d1 solution (10 µg/20 µl PBS) was placed onto the outer 
ear skin. Pricks through the ear skin were performed with 23G (0.6 mm × 
25 mm) needles (Microlance; BD). For intradermal ear prick tests, an rFel d1 
solution (0.6, 2.5, and 10 µg/10 µl PBS) was injected intradermally into the 
ears. Dye extravasations started immediately after antigen challenge. 1 hr 
later, mice were sacrificed and ears were prepared from individual mice for 
evaluation of dye leakage by densitometry. To this end, the area of dye leak-
age was defined within the densitometer by gating around the leaked dye.   
A combination of size and color intensity of the pricked area defines the 
strength of dye leakage per ear, which is expressed as net intensity by the 
densitometer. Mean net intensity of different mice per group is shown.
Acute systemic anaphylaxis. For the induction of anaphylaxis, sensitized 
mice were challenged i.v. with 1 µg rFel d1/200 µl PBS. Temperature was 
measured with a rectal probe digital thermometer (Thermalert TH-5, RET-3; 
Physitemp Instruments INC) immediately after i.v. antigen challenge and mon-
itored for a maximum of 100 min after challenge. For statistical analysis, the area 
above the curve was determined using Prism (GraphPad Software, Inc.).
Analysis of immediate type allergic responses. Sensitized mice were chal-
lenged i.p. with 10 µg rFel d1 in 300 µl PBS 12 d after vaccination with Q or 
Q–Fel d1. Immediately after i.p. challenge, typical signs of anaphylactic reac-
tions, including activity, ear, feet, and skin redness, or swelling, were monitored. 
Pictures were taken 40 min after rFel d1 administration. 1 h after i.p. antigen chal-
lenge, mice were sacrificed and albumin levels and cellular infiltrates in the peri-
toneum were determined as described elsewhere (Sun et al., 2007). In brief, 
peritoneal lavages were centrifuged and cell counts determined from the cell pellet 
with a Coulter Counter (Instrumenten Gesellschaft AG). The content of albumin 
was quantified from peritoneal lavage supernatants with a commercial Bicincho-
ninic Acid kit (Sigma-Aldrich) using a BSA standard curve. Albumin levels of na-
ive mice, challenged with rFel d1 antigen, were used as background levels. Serum 
histamine was determined from plasma of individual mice with an enzyme   
immunoassay kit (DRG Instruments GmbH).
ELISPOT assays
Sensitized BALB/c mice were challenged either i.p. or i.v. with 10 µg rFel d1 
diluted in PBS, 2 wk after Q- and Q–Fel d1 vaccination. Sensitized   
and nonvaccinated mice, challenged either with PBS or rFel d1, were used 
as control mice. 7 d after antigen challenge, spleens of individual mice were 
isolated and single cell suspensions were prepared in IMDM medium, sup-
plemented  with  10%  FCS  and  antibiotics.  For  IFN-  ELISPOT  assays, 
spleen cells of individual mice were threefold titrated in 96-well round bot-
tom plates starting with 3 × 106 cells in the first well. Cells were stimulated 
for 2 d with 200 µl Fel d1 (10 µg/ml), 200 µl PMA/ionomycin (1mM/1mg/ml), 
or medium alone. After 2 d of incubation at 37°C and 7% CO2, cells were 
transferred on IFN-–coated and FCS-blocked ELISPOT plates (Multi-
Screen 96-well plates; Millipore), followed by incubation for a further 24 h 1954 VACCINATION WITH Q–FEL D1 PROTECTS MICE AGAINST CAT ALLERGY | Schmitz et al.
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